HC Wainwright Reaffirms Buy Rating for Aethlon Medical (NASDAQ:AEMD)

Aethlon Medical (NASDAQ:AEMD)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $7.00 price target on the medical equipment provider’s stock.

Separately, StockNews.com started coverage on Aethlon Medical in a research note on Friday, November 8th. They issued a “sell” rating on the stock.

Aethlon Medical Stock Down 1.9 %

Aethlon Medical stock opened at $0.40 on Friday. Aethlon Medical has a one year low of $0.24 and a one year high of $2.35. The business’s fifty day moving average is $0.40 and its 200 day moving average is $0.50.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.10. During the same quarter in the previous year, the company posted ($1.30) EPS. As a group, research analysts anticipate that Aethlon Medical will post -1.1 EPS for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.